US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

429.71

+9.782.33%

Number of Gainers:4

Number of Losers:1

Number of Flat:- -

PE:- -

High:435.49

Open:419.51

Low:411.02

Close:419.93

Volume:15.06M

Turnover:228.77M

Market Cap:8.89B

Float Cap:8.45B

Loading ...

Wolfe downgrades Intellia to Peer Perform on Nex-z safety issue

Intellia Therapeutics Cut to Hold From Buy by Jones Trading

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial

Benzinga_recent_news

Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Guardian Pharmacy Services, Inc. Class A (GRDN)

Intellia Therapeutics Inc : Jonestrading Cuts to Hold Rating

THOMSON REUTERS

Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)

Editas Medicine Reports Q3 2025 Progress and Financials

Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial

Intellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy

Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP)

Dyadic International, ERS Genomics announces CRISPR/Cas9 license

Editas Medicine Q3 net loss narrows, beats expectations

Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials

BRIEF-Editas Medicine Q3 Net Income USD -25.117 Million Vs. IBES Estimate USD -28.1 Million

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

THOMSON REUTERS

Editas Medicine Inc: on Track to Submit Ind/Cta for Edit-401 by Mid-2026, Achieve Initial Human Proof-of-Concept Data by Year-End 2026

THOMSON REUTERS

Editas Medicine Q3 Operating Income USD -24.548 Million

THOMSON REUTERS

Editas Medicine Q3 Net Income USD -25.117 Million VS. Ibes Estimate USD -28.1 Million

THOMSON REUTERS

Intellia Therapeutics Inc : H.c. Wainwright Cuts Target Price to $15 From $18

THOMSON REUTERS

Intellia Therapeutics presents Phase 1/2 data on lonvo-z

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":429.70605,"timestamp":1762894799999,"preClose":419.93094,"halted":0,"volume":15055673,"delay":0,"changeRate":0.023278,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":9.775116,"latestTime":"11-11 16:00:00 EST","open":419.5133,"high":435.48743,"low":411.0237,"amount":228772791.715375,"amplitude":0.058257,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1762957800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.569227,"peRate":-5.232388,"turnoverRate":0.02257,"increases":4,"decrements":1,"flats":0,"marketCap":8889885616,"floatMarketCap":8445071792},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":435.48743,"amplitude":0.058257,"preClose":419.93094,"low":411.0237,"pbRate":"2.569227","latestPrice":429.70605,"volume":15055673,"delay":0,"open":419.5133,"prevYearClose":376.62552,"prevWeekClose":422.9689,"prevMonthClose":498.041,"prevQuarterClose":525.3247,"fiveDayClose":448.929,"twentyDayClose":587.0017,"sixtyDayClose":418.6786,"secType":"PLATE","market":"US","turnoverRate":0.02257,"peRate":-5.232388,"marketCap":8889885616,"floatMarketCap":8445071792,"timestamp":1762894799999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":4,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582244353","title":"Wolfe downgrades Intellia to Peer Perform on Nex-z safety issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2582244353","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582244353?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:55","pubTimestamp":1762941316,"startTime":"0","endTime":"0","summary":"Wolfe Research last night downgraded Intellia Therapeutics (NTLA) to Peer Perform from Outperform without a price target The safety issue for nexig...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wolfe-downgrades-intellia-to-peer-perform-on-nex-z-safety-issue-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wolfe-downgrades-intellia-to-peer-perform-on-nex-z-safety-issue-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTLA","BK4588","BK4585","BK4139","LU1861558580.USD","BK4535","BK4556","LU1861559042.SGD"],"gpt_icon":0},{"id":"2582394032","title":"Intellia Therapeutics Cut to Hold From Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2582394032","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582394032?lang=en_us&edition=fundamental","pubTime":"2025-11-12 04:03","pubTimestamp":1762891380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NTLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 15:03 ET (20:03 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","BK4139","LU1861558580.USD","BK4585","BK4556","BK4535","LU1861559042.SGD","BK4588"],"gpt_icon":0},{"id":"2582046360","title":"CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582046360","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582046360?lang=en_us&edition=fundamental","pubTime":"2025-11-11 22:50","pubTimestamp":1762872600,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48779688/crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/11/48779688/crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["USJW.SI","PSQ","TQQQ","MNQmain","LU1917777945.USD","LU1861558580.USD","LU1861559042.SGD","LU0320765992.SGD","NVIW.SI","LU2362540622.SGD","SQQQ","TSYW.SI","TG","BK4588","LU2468319806.SGD","LU0053666078.USD","CRSP","LU0823434740.USD","BK4556","LU0823434583.USD","BK4090","LU2023250504.SGD","LU2089984988.USD",".IXIC","BK4153","USAW.SI","LU2362541273.HKD","BK4585","LU1974910355.USD","ARWR","LU0058720904.USD","LU0823416689.USD","QID","LU0109394709.USD","LU0882574055.USD","QLD","LU2106854487.HKD","NQmain","LU2362541513.USD","BK4611","LU0114720955.EUR","LDL","LU0289739699.SGD","BK4139","LU0889565916.HKD","REGN","LU2237438978.USD"],"gpt_icon":1},{"id":"2582362335","title":"Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Guardian Pharmacy Services, Inc. Class A (GRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582362335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582362335?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:50","pubTimestamp":1762869018,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Editas Medicine (EDIT – Research Report) and Guard...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-editas-medicine-edit-and-guardian-pharmacy-services-inc-class-a-grdn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-editas-medicine-edit-and-guardian-pharmacy-services-inc-class-a-grdn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HCSG","BK4556","GRDN","BK4128","LABU","XBI","BK4581","BK4588","BK4137","BK4139","EDIT","LU0029874061.USD","BK4196","LU0128526141.USD","XLV"],"gpt_icon":0},{"id":"2582366713","title":"Intellia Therapeutics Inc : Jonestrading Cuts to Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366713?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:37","pubTimestamp":1762864634,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nFWN3WN1C0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4535","LU1861558580.USD","BK4139","NTLA","BK4585","BK4588","BK4556"],"gpt_icon":0},{"id":"2582518533","title":"Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582518533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582518533?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:58","pubTimestamp":1762851500,"startTime":"0","endTime":"0","summary":"Barclays analyst Gena Wang maintained a Hold rating on Crispr Therapeutics AG today and set a price target of $56.00. According to TipRanks, Wang i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-crispr-therapeutics-ag-crsp-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-crispr-therapeutics-ag-crsp-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRSP","BK4139","BK4611","BK4556","BK4585","LU1861558580.USD","BK4588","BK4210","LU1861559042.SGD","AG"],"gpt_icon":0},{"id":"2582339992","title":"Editas Medicine Reports Q3 2025 Progress and Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2582339992","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582339992?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:10","pubTimestamp":1762834226,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. ( ($EDIT) ) has released its Q3 earnings. Here is a breakdown of the information Editas Medicine Inc. presented to its investo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-reports-q3-2025-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-reports-q3-2025-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4556","LU2065732104.USD","EDIT","PRGS","BK4097"],"gpt_icon":0},{"id":"2582771802","title":"Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582771802","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582771802?lang=en_us&edition=fundamental","pubTime":"2025-11-11 04:30","pubTimestamp":1762806622,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) announced “positive” follow-up data from the ongoing Phase 1 clinical trial of its investigational product nexiguran z...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-announces-positive-follow-up-data-from-ongoing-phase-1-nex-z-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-announces-positive-follow-up-data-from-ongoing-phase-1-nex-z-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTLA","BK4139","BK4535","BK4556","BK4588","LU1861559042.SGD","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"2582802495","title":"Intellia Therapeutics Reports Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in ATTR Amyloidosis Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2582802495","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582802495?lang=en_us&edition=fundamental","pubTime":"2025-11-11 04:23","pubTimestamp":1762806214,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc. announced positive follow-up data from its ongoing Phase 1 clinical trial of nexiguran ziclumeran , an investigational therapy for patients with transthyretin  amyloidosis with cardiomyopathy. The results were presented at the American Heart Association  Scientific Sessions 2025 in New Orleans. According to the company, a single dose of nex-z resulted in a rapid, deep, and durable reduction in serum transthyretin  levels, with stability or improvement in multiple markers of cardiomyopathy observed at 24 months. Nex-z was generally well tolerated, with the most common treatment-related adverse events being infusion-related reactions and transaminase elevations, none exceeding Grade 2. Deaths reported during the study were attributed to the progression of underlying cardiovascular disease. Longer-term safety data were consistent with previous reports from the Phase 1 trial.Disclaimer: This news brief was created by Public Technologies  using generative artifici","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLvd3S2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861559042.SGD","BK4585","NTLA","BK4139","LU1861558580.USD","BK4556","BK4535"],"gpt_icon":0},{"id":"2582087198","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582087198","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582087198?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:10","pubTimestamp":1762780226,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on AMN Healthcare Services (AMN – Research Report) and Crispr Therap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amn-healthcare-services-amn-and-crispr-therapeutics-ag-crsp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amn-healthcare-services-amn-and-crispr-therapeutics-ag-crsp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","BK4210","BK4139","LABU","BK4556","AMN","BK4581","BK4588","XLV","CRSP","AG","LU1861559042.SGD","LU1861558580.USD","BK4585","BK4196","BK4611","HCAR"],"gpt_icon":0},{"id":"2582876132","title":"Dyadic International, ERS Genomics announces CRISPR/Cas9 license","url":"https://stock-news.laohu8.com/highlight/detail?id=2582876132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582876132?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:38","pubTimestamp":1762778286,"startTime":"0","endTime":"0","summary":"ERS Genomics and Dyadic International (DYAI) announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 pat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyadic-international-ers-genomics-announces-crispr-cas9-license-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyadic-international-ers-genomics-announces-crispr-cas9-license-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","LU1861558580.USD","LU1861559042.SGD","DYAI","BK4611","CRSP","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2582873084","title":"Editas Medicine Q3 net loss narrows, beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873084","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873084?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:08","pubTimestamp":1762776515,"startTime":"0","endTime":"0","summary":"Editas Medicine Q3 net loss narrows, beats expectationsOverviewEditas Q3 net loss decreases to $25.1 mln, beating analyst expectationsCollaboration revenue rises to $7.5 mln, driven by BMS milestone a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","EDIT"],"gpt_icon":0},{"id":"2582873789","title":"Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873789","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873789?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:05","pubTimestamp":1762776332,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association  and the European Society of Gene and Cell Therapy , demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug  or clinical trial application  for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual Evercore Healthcare Conference on December 2, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL49YDmy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVR","BK4139","BK4556","BK4127","EDIT"],"gpt_icon":0},{"id":"2582873668","title":"BRIEF-Editas Medicine Q3 Net Income USD -25.117 Million Vs. IBES Estimate USD -28.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873668","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873668?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776047,"startTime":"0","endTime":"0","summary":"Nov 10  - Editas Medicine Q3 operating expenses USD 32.091 million.Q3 collaboration and other research and development revenue USD 7.5 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"gpt_icon":0},{"id":"2582873359","title":"Editas Medicine Announces Third Quarter 2025 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873359?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUADXJK3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EDIT","BK4556"],"gpt_icon":0},{"id":"2582875342","title":"Editas Medicine Inc: on Track to Submit Ind/Cta for Edit-401 by Mid-2026, Achieve Initial Human Proof-of-Concept Data by Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875342?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","EDIT","BK4139"],"gpt_icon":0},{"id":"2582873333","title":"Editas Medicine Q3 Operating Income USD -24.548 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873333","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873333?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","EDIT","BK4139"],"gpt_icon":0},{"id":"2582187388","title":"Editas Medicine Q3 Net Income USD -25.117 Million VS. Ibes Estimate USD -28.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582187388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582187388?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EDIT","BK4556"],"gpt_icon":0},{"id":"2582820054","title":"Intellia Therapeutics Inc : H.c. Wainwright Cuts Target Price to $15 From $18","url":"https://stock-news.laohu8.com/highlight/detail?id=2582820054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582820054?lang=en_us&edition=fundamental","pubTime":"2025-11-10 19:31","pubTimestamp":1762774302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nFWN3WM0YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861558580.USD","BK4139","BK4535","LU1861559042.SGD","NTLA","BK4585","BK4588","BK4556"],"gpt_icon":0},{"id":"2582581809","title":"Intellia Therapeutics presents Phase 1/2 data on lonvo-z","url":"https://stock-news.laohu8.com/highlight/detail?id=2582581809","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582581809?lang=en_us&edition=fundamental","pubTime":"2025-11-10 02:25","pubTimestamp":1762712706,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) presented positive clinical data from a pooled analysis of all patients who received a 50 milligram dose of lonvo-z in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-presents-phase-1-2-data-on-lonvo-z-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-presents-phase-1-2-data-on-lonvo-z-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4556","BK4535","NTLA","LU1861558580.USD","LU1861559042.SGD","BK4139","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}]}}